Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Imaging Microglial/Macrophage Activation in Spinal Cords of Experimental Autoimmune Encephalomyelitis Rats by Positron Emission Tomography Using the Mitochondrial 18 kDa Translocator Protein Radioligand [18F]DPA-714.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Patient page. Multiple sclerosis and vitamin D.
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
Transcriptomics: mRNA and alternative splicing.
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Drugs to be Discontinued
Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
Food and Drug Administration briefing document for ofatumumab
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.

Pages